Last Price | 60.55 | Max Price | 121.95 |
Min Price | 55.75 | 1 Year return | -48.64 |
Avg. Target | 82.75 | Expected Return | 36.66 % |
Sector | Health Care | Subsector | Pharmaceuticals |
Sell | 2 | Rating | |
Hold | 3 | Concensus | |
Buy | 3 | ||
Annual report 2016 |
Contact info:Street: Goeschwitzer Strasse 51-52Zip Code: 07745City: JenaCountry: GermanyPhone: 49 3641 220 0Email: investors.meditec@zeiss.comWebsite: www.zeiss.comCEO: Ludwin MonzCFO: Dr. Christian Müller
Year | Turnover | Total sector | Market share |
---|---|---|---|
2019 | 1,459 | 615,634 | 0.24 % |
2020 | 1,335 | 638,070 | 0.21 % |
2021 | 1,647 | 727,968 | 0.23 % |
2022 | 1,903 | 787,273 | 0.24 % |
2023 | 0 | 0 | 0.00 % |
Analysts: this year best year ever for Carl Zeiss Meditec
Analysts expect over 2021 rising revenue Carl Zeiss Meditec
Analysts foresee more revenue Carl Zeiss Meditec
Analysts expect over 2020 rising revenue Carl Zeiss Meditec
Analysts expect revenue increase Carl Zeiss Meditec
2017 | 2018 | 2019 | 2020 | 2021 |
---|---|---|---|---|
Carl Zeiss Meditec's head office is located in Jena. Carl Zeiss Meditec's core business is the pharmaceutical sector. Ludwin Monz is leading the company as CEO. Dr. Christian M�ller runs the company as a CFO. The global pharmaceutical companies gained around 75 percent over the last 10 years. As from 2011 the sector is 147 percent higher and over the past 12 months (December 2015-December 2016) there is a minus of 75 percent.
Over the last 12 months (from December 2015 till December 2016), that were profitable period for the investors in Carl Zeiss Meditec, the stock gained around 18 percent. The period between August 2011 and August 2016 was a good period for the investors. The stock rose around 124 percent. Carl Zeiss Meditec's revenues between 2011 and 2015 were relatively steady and moved between 861,88 million euros and 1,04 billion euros. The net results between 2011 and 2015 were very constant and fluctuated between 72,27 million euros and 65,56 million euros.
The German company paid out dividends in the past 5 years. On average the Carl Zeiss Meditec stock yielded a delivered a dividend yield of around 1,93 percent over the past 5 years.
At the end of 2015 the company had around 2972 thousand people employed.
At the end of 2015 the German company's balance sheet was worth 1,14 billion euros. The total debt was around 385,43 million euros. This is 33,83 percent of the total balance sheet. Last year the pharmaceutical company's price/earnings-ratio (PE) was around 27. So the investors valued the stock at 27 times 2015' earnings per share. Based on it's price/earnings-ratio and dividend yield the German stock can be seen as a value stock.
At the end of 2015 the market capitalization (the number of shares outstanding multiplied by the stock price) of the pharmaceutical company equaled around 2,25 billion euros. At the end of 2015 the German company had around 81,31 million stocks listed on the stock exchange(s).
All the annual reports of Carl Zeiss Meditec are available here. More information about Carl Zeiss Meditec can be found it's website. .
Results |
2015
|
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|---|
Revenue |
1,040
|
1,088
|
1,190
|
1,281
|
1,459
|
1,335
|
Costs |
978
|
990
|
1,055
|
1,154
|
1,300
|
1,213
|
Profit |
62
|
98
|
134
|
126
|
160
|
122
|
Margin of profit |
5.99
|
9.03
|
11.30
|
9.87
|
10.95
|
9.16
|
ROI |
8.26
|
12.32
|
11.06
|
9.78
|
11.42
|
8.55
|
Balance |
2015
|
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|---|
Equity |
754
|
798
|
1,215
|
1,293
|
1,398
|
1,432
|
Debt |
385
|
450
|
408
|
369
|
624
|
583
|
Total assets |
1,139
|
1,248
|
1,623
|
1,662
|
2,022
|
2,015
|
Solvency |
66.17
|
63.94
|
74.88
|
77.82
|
69.16
|
71.06
|
Cash |
13
|
9
|
8
|
8
|
23
|
6
|
Cashflow |
57
|
112
|
38
|
187
|
220
|
179
|
Employees |
0
|
0
|
0
|
0
|
0
|
|
Revenue per employee |
0.0
|
0.0
|
0.0
|
0.0
|
0.0
|
|
Cashflow / Debt |
0.15
|
0.25
|
0.09
|
0.51
|
0.35
|
0.31
|
Details |
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|
Price |
28.55
|
35.00
|
51.76
|
68.30
|
113.70
|
Eps |
1.21
|
1.57
|
1.41
|
1.79
|
1.37
|
Price/earnings-ratio |
23.60
|
22.29
|
36.71
|
38.16
|
44.20
|
Dividend |
0.42
|
0.55
|
0.55
|
0.65
|
0.50
|
Dividend % |
1.47 %
|
1.57 %
|
1.06 %
|
0.95 %
|
0.83 %
|
Payout % |
0.35
|
0.35
|
0.39
|
0.36
|
0.36
|
Book value |
9.81
|
13.59
|
14.46
|
15.64
|
16.01
|
Market to book |
0.34
|
0.39
|
0.28
|
0.23
|
0.26
|
Cashflow per stock |
1.37
|
0.42
|
2.09
|
2.46
|
2.00
|
Stocks |
81
|
89
|
89
|
89
|
89
|
Market Cap |
2.321.39
|
3.130.42
|
4.629.45
|
6.108.79
|
5.415.63
|
Date
|
Price
|
---|---|
31 Oct 2024
|
60.55
|
29 Oct 2024
|
62.35
|
23 Oct 2024
|
61.95
|
19 Oct 2024
|
64.80
|
16 Oct 2024
|
61.25
|
14 Oct 2024
|
65.75
|
05 Oct 2024
|
69.05
|
02 Oct 2024
|
66.30
|
27 Sep 2024
|
65.90
|
20 Sep 2024
|
59.25
|
17 Sep 2024
|
57.00
|
13 Sep 2024
|
55.75
|
28 Aug 2024
|
65.00
|
26 Aug 2024
|
62.70
|
23 Aug 2024
|
62.55
|
11 Aug 2024
|
63.75
|
07 Aug 2024
|
61.65
|
05 Aug 2024
|
60.90
|
01 Aug 2024
|
63.35
|
30 Jul 2024
|
61.60
|
26 Jul 2024
|
60.50
|
23 Jul 2024
|
62.25
|
16 Jul 2024
|
64.40
|
10 Jul 2024
|
64.30
|
09 Jul 2024
|
65.50
|
04 Jul 2024
|
65.00
|
02 Jul 2024
|
66.00
|
26 Jun 2024
|
66.00
|
21 Jun 2024
|
100.00
|
19 Jun 2024
|
100.00
|